Epizyme Inc. (NASDAQ:EPZM)‘s stock had its “buy” rating restated by analysts at JMP Securities in a note issued to investors on Sunday.
Several other brokerages have also commented on EPZM. Zacks Investment Research lowered Epizyme from a “buy” rating to a “sell” rating in a research note on Tuesday, July 12th. HC Wainwright restated a “buy” rating on shares of Epizyme in a research note on Sunday, November 6th. Leerink Swann reaffirmed an “outperform” rating on shares of Epizyme in a research report on Friday, October 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Epizyme in a research report on Friday, November 4th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $23.11.
Epizyme (NASDAQ:EPZM) remained flat at $11.70 during midday trading on Friday. 160,411 shares of the stock traded hands. The company’s market capitalization is $678.73 million. The firm’s 50 day moving average is $9.88 and its 200-day moving average is $9.77. Epizyme has a one year low of $7.02 and a one year high of $18.29.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.18. The firm had revenue of $6.60 million for the quarter. Epizyme had a negative return on equity of 41.56% and a negative net margin of 1,205.01%. Equities research analysts anticipate that Epizyme will post ($1.98) EPS for the current year.
Large investors have recently modified their holdings of the stock. BlackRock Group LTD increased its stake in shares of Epizyme by 3.7% in the third quarter. BlackRock Group LTD now owns 10,374 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 371 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Epizyme during the second quarter valued at $104,000. HBK Investments L P acquired a new stake in shares of Epizyme during the first quarter valued at $149,000. State Board of Administration of Florida Retirement System increased its stake in shares of Epizyme by 15.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,347 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,102 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Epizyme during the first quarter valued at $184,000. 80.13% of the stock is currently owned by institutional investors.
Epizyme Company Profile